An Open-label, International, Multicenter, Single-arm, Uncontrolled, Phase IIIb Study of Riociguat in Patients With Pulmonary Arterial Hypertension (PAH) Who Demonstrate an Insufficient Response to Treatment With Approved Dosages of Phosphodiesterase-5 Inhibitors (PDE-5i)

Trial Profile

An Open-label, International, Multicenter, Single-arm, Uncontrolled, Phase IIIb Study of Riociguat in Patients With Pulmonary Arterial Hypertension (PAH) Who Demonstrate an Insufficient Response to Treatment With Approved Dosages of Phosphodiesterase-5 Inhibitors (PDE-5i)

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Riociguat (Primary)
  • Indications Pulmonary hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms RESPITE
  • Sponsors Bayer
  • Most Recent Events

    • 01 Sep 2017 Primary endpoint (Change from baseline in 6 minute walking distance) has been met, according to the results published in the European Respiratory Journal.
    • 01 Sep 2017 Results published in the European Respiratory Journal
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top